The association between SGLT2 inhibitors and new-onset arrhythmias: a nationwide population-based longitudinal cohort study

Table 3 Sensitivity analyses

Outcome	Non-SGLT2i			SGLT2i			Hazard Ratio	P value
Outcome	%	20 M KM (%)	Events/10,000 Ptms	%	20 KM (%)	Events/10,000 Ptms	(95% CI)	P value
Age < 60 year and All-cause death	305 (0.60%)	0.60	6.42	147 (0.29%)	0.29	3.05	0.47 (0.35–0.63)	< 0.001
Age ≥ 60 year and All-cause death	361 (1.26%)	1.26	13.94	233 (0.81%)	0.81	8.93	0.57 (0.45–0.72)	< 0.001
Age < 60 year and NOA	452 (0.89%)	0.87	9.58	369 (0.73%)	0.72	7.70	0.81 (0.67–0.99)	0.042
Age ≥ 60 year and NOA	406 (1.42%)	1.40	15.82	352 (1.23%)	1.21	13.60	0.83 (0.68–1.01)	0.061

NOA new-onset arrhythmias, 10,000 Ptms per 10,000 patient months, SGLT2i sodium–glucose cotransporter 2 inhibitors

ISSN: 1475-2840